Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-25T00:35:15.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of new collaborators and a revision number change, while extensive details about the study's design, inclusion and exclusion criteria have been removed.
    Difference
    24%
    Check dated 2025-04-17T21:11:19.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 7, 2025, while a date for March 25, 2025, has been removed.
    Difference
    0.2%
    Check dated 2025-04-10T17:11:30.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous estimated update date of January 7, 2025, and revision version 2.14.2.
    Difference
    0.1%
    Check dated 2025-04-02T02:36:47.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.6%
    Check dated 2025-02-25T05:54:28.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.6%
    Check dated 2025-02-10T18:26:59.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.